Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T69494
|
||||
Former ID |
TTDS00135
|
||||
Target Name |
NMDA receptor
|
||||
Target Type |
Successful
|
||||
Disease | Anaesthesia; Anxiety disorder [ICD9:338, 300, 311; ICD10: R52, G89, F32, F40-F42] | ||||
Anesthesia [ICD9: 338; ICD10: R20.0] | |||||
Acute ischemic stroke [ICD9: 434.91; ICD10: I61-I63] | |||||
Acute pain [ICD9: 338,780; ICD10: R52, G89] | |||||
Alzheimer disease [ICD9: 331; ICD10: G30] | |||||
Bacterial infections [ICD9: 001-009, 010-018, 020-027, 030-041, 080-088, 090-099, 100-104; ICD10: A00-B99] | |||||
Cancer pain [ICD9: 140-229, 338,780; ICD10: R52, G89] | |||||
Cerebral infarction [ICD10: I63] | |||||
Cognitive disorders [ICD9: 290-294, 294.0, 780.09, 780.9, 780.93; ICD10: F01-F07, F04, F05, R41.3] | |||||
Cerebrovascular ischaemia [ICD9: 434.91; ICD10: I61-I63] | |||||
Dementia [ICD9: 290-294; ICD10: F01-F07] | |||||
Depression [ICD9: 311; ICD10: F30-F39] | |||||
Exogenous obesity [ICD10: E66] | |||||
Epileptic seizures; Alzheimer disease [ICD9:345.9, 780.3, 331; ICD10: G40, P90, R56, G30] | |||||
Epilepsy [ICD10: G40] | |||||
Epileptic seizures [ICD9: 345.9, 780.3; ICD10: G40, P90, R56] | |||||
Major depressive disorder [ICD9: 296.2, 296.3, 710.0; ICD10: F32, F33, M32] | |||||
Neurological disease [ICD9: 338, 338.2, 410, 782.3,780; ICD10: I21, I22, R52, R52.1-R52.2, R60.9, G89] | |||||
Neuropathy [ICD9: 356.0, 356.8; ICD10: G64, G90.0] | |||||
Neurodegenerative disease [ICD9: 330-337; ICD10: G30-G32] | |||||
Neuropathic pain [ICD9: 356.0, 356.8; ICD10: G64, G90.0] | |||||
Obsessive compulsive disorder [ICD9: 300.3; ICD10: F42] | |||||
Parkinson's disease [ICD9: 332; ICD10: G20] | |||||
Painful diabetic neuropathy [ICD9: 250.6,338,780; ICD10: E10.4, E11.4, E13.4, G89, R52] | |||||
Pain [ICD9: 338, 356.0, 356.8,780; ICD10: G64, G90.0, R52, G89] | |||||
Suicidal ideation [ICD10: R45.8] | |||||
Schizophrenia [ICD9: 295; ICD10: F20] | |||||
Schizophrenia; Indigestion [ICD9:295; ICD10: F20, K30] | |||||
Traumatic brain injury [ICD9: 800.0-801.9, 803.0-804.9, 850.0-854.1; ICD10: S06] | |||||
BioChemical Class |
Ion transport
|
||||
Target Validation |
T69494
|
||||
Drugs and Mode of Action | |||||
Drug(s) | Benzphetamine | Drug Info | Approved | Exogenous obesity | [551871] |
D-cycloserine | Drug Info | Approved | Bacterial infections | [536854] | |
Felbamate | Drug Info | Approved | Epilepsy | [536756], [540874] | |
Huperzine A | Drug Info | Approved | Epileptic seizures; Alzheimer disease | [544707], [551871] | |
Ketamine | Drug Info | Approved | Anesthesia | [467569], [536308] | |
L-Glutamic Acid | Drug Info | Approved | Schizophrenia; Indigestion | [536838], [538847], [551871] | |
Magnesium | Drug Info | Approved | Acute ischemic stroke | [537116] | |
Magnesium Sulfate | Drug Info | Approved | Acute pain | [537116] | |
Memantine | Drug Info | Approved | Alzheimer disease | [467588], [528380] | |
Nitrous oxide | Drug Info | Approved | Anaesthesia; Anxiety disorder | [536300], [551871] | |
Orphenadrine | Drug Info | Approved | Parkinson's disease | [538173], [542269] | |
Amitriptyline+ketamine | Drug Info | Phase 3 | Neuropathic pain | [544412] | |
Dexanabinol | Drug Info | Phase 3 | Traumatic brain injury | [537115] | |
Remacemide | Drug Info | Phase 3 | Pain | [534082] | |
AV-101 | Drug Info | Phase 2 | Neuropathic pain | [525245] | |
CHF-3381 | Drug Info | Phase 2 | Neuropathic pain | [529017], [536374] | |
CNS-5161 | Drug Info | Phase 2 | Neuropathic pain | [536374] | |
D-cycloserine | Drug Info | Phase 2 | Obsessive compulsive disorder | [536854] | |
Dextromethorphan+quinidine | Drug Info | Phase 2 | Painful diabetic neuropathy | [536078] | |
Dimiracetam | Drug Info | Phase 2 | Neuropathic pain | [523061] | |
MDL-27192 | Drug Info | Phase 2 | Epileptic seizures | [546020] | |
Neramexane | Drug Info | Phase 2 | Cancer pain | [536058] | |
NRX-1074 | Drug Info | Phase 2 | Major depressive disorder | [524651] | |
TRAXOPRODIL MESYLATE | Drug Info | Phase 2 | Neurological disease | [521688] | |
ADCI | Drug Info | Phase 1 | Epileptic seizures | [525718] | |
ASP-0777 | Drug Info | Phase 1 | Alzheimer disease | [523568] | |
AZD6423 | Drug Info | Phase 1 | Suicidal ideation | [524408] | |
AD-529 | Drug Info | Preclinical | Neuropathic pain | [548142] | |
ADX-2 series | Drug Info | Preclinical | Schizophrenia | [536463] | |
ED-1812 | Drug Info | Preclinical | Pain | [548142] | |
Midafotel | Drug Info | Discontinued in Phase 3 | Cognitive disorders | [545291] | |
Selfotel | Drug Info | Discontinued in Phase 3 | Cerebrovascular ischaemia | [467500], [544835] | |
AZD6765 | Drug Info | Discontinued in Phase 2 | Major depressive disorder | [542661], [548584] | |
EAA-090 | Drug Info | Discontinued in Phase 2 | Painful diabetic neuropathy | [536374] | |
SGS-111 | Drug Info | Discontinued in Phase 2 | Cognitive disorders | [547578] | |
CGP-37849 | Drug Info | Discontinued in Phase 1 | Neurological disease | [467499], [546401] | |
Delucemine | Drug Info | Discontinued in Phase 1 | Depression | [546633] | |
S-1746 | Drug Info | Discontinued in Phase 1 | Cerebrovascular ischaemia | [547450] | |
ACEA-1011 | Drug Info | Terminated | Cerebral infarction | [546400] | |
ACEA-1031 | Drug Info | Terminated | Cerebrovascular ischaemia | [546460] | |
ACEA-1328 | Drug Info | Terminated | Cancer pain | [546357] | |
ACEA-1416 | Drug Info | Terminated | Cerebrovascular ischaemia | [546407] | |
CNS-1531 | Drug Info | Terminated | Neuropathy | [545051] | |
CNS-5788 | Drug Info | Terminated | Cerebrovascular ischaemia | [547184] | |
Dextrorphan | Drug Info | Terminated | Acute ischemic stroke | [546637] | |
FR-115427 | Drug Info | Terminated | Cerebrovascular ischaemia | [546642] | |
GPI-3000 | Drug Info | Terminated | Cerebrovascular ischaemia | [544990] | |
IDRA-21 | Drug Info | Terminated | Alzheimer disease | [467553], [527059] | |
L-689560 | Drug Info | Terminated | Neurodegenerative disease | [467573], [544995] | |
L-698544 | Drug Info | Terminated | Alzheimer disease | [545425] | |
LY-274614 | Drug Info | Terminated | Dementia | [544875] | |
M-241247 | Drug Info | Terminated | Cerebrovascular ischaemia | [545475] | |
NPS-1392 | Drug Info | Terminated | Cerebrovascular ischaemia | [547110] | |
PD-158473 | Drug Info | Terminated | Cerebrovascular ischaemia | [546428] | |
PD-159913 | Drug Info | Terminated | Cerebrovascular ischaemia | [546429] | |
Modulator | ACEA-1011 | Drug Info | [533995] | ||
ACEA-1031 | Drug Info | [533702] | |||
ACEA-1416 | Drug Info | [534653] | |||
ACPC | Drug Info | [533815], [551871] | |||
ADCI | Drug Info | [525718] | |||
ASP-0777 | Drug Info | [551922] | |||
CGP-37849 | Drug Info | [530393] | |||
CNS-1531 | Drug Info | [550138] | |||
Delucemine | Drug Info | [525692] | |||
FR-115427 | Drug Info | [533718] | |||
GPI-3000 | Drug Info | [534607] | |||
IDRA-21 | Drug Info | [527059] | |||
L-689560 | Drug Info | [526795] | |||
L-698544 | Drug Info | [533941] | |||
LY-274614 | Drug Info | [533610] | |||
MDL-27192 | Drug Info | [534392], [551871] | |||
Memantine | Drug Info | [526721], [551871] | |||
Midafotel | Drug Info | [531509] | |||
PD-158473 | Drug Info | [526459] | |||
PD-159913 | Drug Info | [550138] | |||
SGS-111 | Drug Info | [544121] | |||
TRAXOPRODIL MESYLATE | Drug Info | [527945], [551871] | |||
Antagonist | ACEA-1328 | Drug Info | [536058] | ||
AD-529 | Drug Info | [550138] | |||
ADX-2 series | Drug Info | [536463] | |||
Amitriptyline+ketamine | Drug Info | [536374] | |||
Aptiganel HCl | Drug Info | [535658] | |||
AV-101 | Drug Info | [551769] | |||
AZD6423 | Drug Info | [543994] | |||
AZD6765 | Drug Info | [550288] | |||
Benzphetamine | Drug Info | [535378] | |||
C-101,606 | Drug Info | [535404] | |||
CHF-3381 | Drug Info | [536374] | |||
CNS-5161 | Drug Info | [536374] | |||
CNS-5788 | Drug Info | [525990] | |||
Dexanabinol | Drug Info | [537115] | |||
Dextromethorphan+quinidine | Drug Info | [536374] | |||
Dextrorphan | Drug Info | [535658] | |||
Dimiracetam | Drug Info | [532652] | |||
EAA-090 | Drug Info | [536374] | |||
ED-1812 | Drug Info | [550138] | |||
Felbamate | Drug Info | [536399], [536617], [536643] | |||
Huperzine A | Drug Info | [536934] | |||
Ketamine | Drug Info | [536166], [537586], [537702] | |||
L-Glutamic Acid | Drug Info | [536888] | |||
M-241247 | Drug Info | [545476] | |||
Magnesium | Drug Info | [537116] | |||
Magnesium Sulfate | Drug Info | [536484] | |||
Neramexane | Drug Info | [536058] | |||
Nitrous oxide | Drug Info | [536300] | |||
NPS-1392 | Drug Info | [525561] | |||
Orphenadrine | Drug Info | [537076], [538036] | |||
S-1746 | Drug Info | [528007] | |||
Selfotel | Drug Info | [535658] | |||
Agonist | D-cycloserine | Drug Info | [536773], [536854] | ||
NRX-1074 | Drug Info | [532574] | |||
Remacemide | Drug Info | [535658], [536166] | |||
References | |||||
Ref 467499 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4154). | ||||
Ref 467500 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4155). | ||||
Ref 467553 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4219). | ||||
Ref 467569 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4233). | ||||
Ref 467573 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4239). | ||||
Ref 467588 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4253). | ||||
Ref 521688 | ClinicalTrials.gov (NCT00163059) The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD. U.S. National Institutes of Health. | ||||
Ref 523061 | ClinicalTrials.gov (NCT01135251) Safety and Preliminary Evidence of Efficacy of Escalating Doses of Dimiracetam in AIDS Patients With Painful Neuropathy. U.S. National Institutes of Health. | ||||
Ref 523568 | ClinicalTrials.gov (NCT01406145) A Study of the Safety and Tolerability of ASP0777 in Subjects With Alzheimer's Disease (AD) Taking a Stable Dose of Donepezil. U.S. National Institutes of Health. | ||||
Ref 524408 | ClinicalTrials.gov (NCT01926366) AZD6423 SAD/MAD Study in Healthy Volunteers. U.S. National Institutes of Health. | ||||
Ref 524651 | ClinicalTrials.gov (NCT02067793) Study of Intravenous NRX-1074 in Patients With Major Depressive Disorder. U.S. National Institutes of Health. | ||||
Ref 525245 | ClinicalTrials.gov (NCT02484456) Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder. | ||||
Ref 525718 | The anticonvulsant SGB-017 (ADCI) blocks voltage-gated sodium channels in rat and human neurons: comparison with carbamazepine. Epilepsia. 2000 Mar;41(3):263-70. | ||||
Ref 527059 | IDRA-21, a positive AMPA receptor modulator, inhibits synaptic and extrasynaptic NMDA receptor mediated events in cultured cerebellar granule cells. Neuropharmacology. 2004 Jun;46(8):1105-13. | ||||
Ref 528380 | Treatment effect size of memantine therapy in Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord. 2006 Jul-Sep;20(3):133-7. | ||||
Ref 529017 | Indantadol, a novel NMDA antagonist and nonselective MAO inhibitor for the potential treatment of neuropathic pain. IDrugs. 2007 Sep;10(9):636-44. | ||||
Ref 534082 | Block of the N-methyl-D-aspartate receptor by remacemide and its des-glycine metabolite. J Pharmacol Exp Ther. 1996 Jan;276(1):161-8. | ||||
Ref 536058 | Emerging analgesics in cancer pain management. Expert Opin Emerg Drugs. 2005 Feb;10(1):151-71. | ||||
Ref 536078 | Dextromethorphan/quinidine: AVP 923, dextromethorphan/cytochrome P450-2D6 inhibitor, quinidine/dextromethorphan. Drugs R D. 2005;6(3):174-7. | ||||
Ref 536300 | Anaesthetic drugs: linking molecular actions to clinical effects. Curr Pharm Des. 2006;12(28):3665-79. | ||||
Ref 536308 | Calcium channel blockers in the spectrum of antihypertensive agents. Expert Opin Pharmacother. 2006 Dec;7(17):2385-401. | ||||
Ref 536463 | The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. Epub 2007 Jul 31. | ||||
Ref 536756 | Use of second-generation antiepileptic drugs in the pediatric population. Paediatr Drugs. 2008;10(4):217-54. | ||||
Ref 536838 | Emerging drugs for chemotherapy-induced mucositis. Expert Opin Emerg Drugs. 2008 Sep;13(3):511-22. | ||||
Ref 536854 | Has nature already identified all useful antibacterial targets? Curr Opin Microbiol. 2008 Oct;11(5):387-92. Epub 2008 Oct 6. | ||||
Ref 537115 | Emerging treatments for traumatic brain injury. Expert Opin Emerg Drugs. 2009 Mar;14(1):67-84. | ||||
Ref 538173 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 040249. | ||||
Ref 538847 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1369). | ||||
Ref 540874 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5473). | ||||
Ref 542269 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7251). | ||||
Ref 542661 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7681). | ||||
Ref 544412 | A Phase III Randomized, Placebo-Controlled Study of Topical Amitriptyline and Ketamine for Chemotherapy-Induced Peripheral Neuropathy (CIPN): A University of Rochester CCOP Study of 462 Cancer Survivors. Support Care Cancer. 2014 July; 22(7): 1807-1814. | ||||
Ref 544707 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000687) | ||||
Ref 544835 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001276) | ||||
Ref 544875 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001393) | ||||
Ref 544990 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001817) | ||||
Ref 544995 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001828) | ||||
Ref 545051 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001975) | ||||
Ref 545291 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002722) | ||||
Ref 545425 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003218) | ||||
Ref 545475 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003415) | ||||
Ref 546020 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005914) | ||||
Ref 546357 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007690) | ||||
Ref 546400 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007916) | ||||
Ref 546401 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007917) | ||||
Ref 546407 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007961) | ||||
Ref 546428 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008060) | ||||
Ref 546429 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008061) | ||||
Ref 546460 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008256) | ||||
Ref 546633 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009310) | ||||
Ref 546637 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009336) | ||||
Ref 546642 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009401) | ||||
Ref 547110 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013127) | ||||
Ref 547184 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013711) | ||||
Ref 547450 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016496) | ||||
Ref 547578 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017512) | ||||
Ref 548142 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022365) | ||||
Ref 525561 | Synthesis, biological activity, and absolute stereochemical assignment of NPS 1392: a potent and stereoselective NMDA receptor antagonist. Bioorg Med Chem Lett. 1999 Jul 19;9(14):1915-20. | ||||
Ref 525692 | NPS 1506, a novel NMDA receptor antagonist and neuroprotectant. Review of preclinical and clinical studies. Ann N Y Acad Sci. 1999;890:450-7. | ||||
Ref 525718 | The anticonvulsant SGB-017 (ADCI) blocks voltage-gated sodium channels in rat and human neurons: comparison with carbamazepine. Epilepsia. 2000 Mar;41(3):263-70. | ||||
Ref 525990 | Identification and characterization of a potential ischemia-selective N-methyl-D-aspartate (NMDA) receptor ion-channel blocker, CNS 5788. Bioorg Med Chem Lett. 2001 Feb 26;11(4):501-4. | ||||
Ref 526459 | Improved intestinal transport of PD 158473, an N-methyl-D-aspartate (NMDA) antagonist, by involvement of multiple transporters. J Pharm Sci. 2002 Dec;91(12):2579-87. | ||||
Ref 526721 | The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry. 2003 Sep;18(Suppl 1):S23-32. | ||||
Ref 526795 | Characterization of the binding of [3H]L-689,560, an antagonist for the glycine site on the N-methyl-D-aspartate receptor, to rat brain membranes. Mol Pharmacol. 1992 May;41(5):923-30. | ||||
Ref 527059 | IDRA-21, a positive AMPA receptor modulator, inhibits synaptic and extrasynaptic NMDA receptor mediated events in cultured cerebellar granule cells. Neuropharmacology. 2004 Jun;46(8):1105-13. | ||||
Ref 527945 | J Neurotrauma. 2005 Dec;22(12):1428-43.The effect of the selective NMDA receptor antagonist traxoprodil in the treatment of traumatic brain injury. | ||||
Ref 530393 | The competitive NMDA receptor antagonists CGP 37849 and CGP 39551 are potent, orally-active anticonvulsants in rodents. Naunyn Schmiedebergs Arch Pharmacol. 1990 Jul;342(1):61-6. | ||||
Ref 531509 | D-CPP-ene (SDZ EAA 494), a potent and competitive N-methyl-D-aspartate (NMDA) antagonist: effect on spontaneous activity and NMDA-induced depolarizations in the rat neocortical slice preparation, compared with other CPP derivatives and MK-801. Neurosci Lett. 1990 Jun 8;113(3):315-21. | ||||
Ref 532574 | Neuroplasticity and the next wave of antidepressant strategies. Front Cell Neurosci. 2013 Nov 20;7:218. | ||||
Ref 532652 | Broad spectrum and prolonged efficacy of dimiracetam in models of neuropathic pain. Neuropharmacology. 2014 Jun;81:85-94. | ||||
Ref 533610 | The NMDA receptor antagonists, LY274614 and MK-801, and the nitric oxide synthase inhibitor, NG-nitro-L-arginine, attenuate analgesic tolerance to the mu-opioid morphine but not to kappa opioids. Pain. 1994 Jan;56(1):69-75. | ||||
Ref 533702 | In vitro pharmacology of ACEA-1021 and ACEA-1031: systemically active quinoxalinediones with high affinity and selectivity for N-methyl-D-aspartate receptor glycine sites. Mol Pharmacol. 1995 Mar;47(3):568-81. | ||||
Ref 533718 | Non-competitive NMDA antagonists, FR115427 and MK801, enhance neuronal survival in primary culture. Neurosci Lett. 1995 Feb 9;185(2):107-10. | ||||
Ref 533815 | 1-Aminocyclopropane carboxylic acid (ACPC) prevents mu and delta opioid tolerance. Life Sci. 1994;55(18):1393-8. | ||||
Ref 533941 | 3-Nitro-3,4-dihydro-2(1H)-quinolones. Excitatory amino acid antagonists acting at glycine-site NMDA and (RS)-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. J Med Chem. 1993 Oct 29;36(22):3397-408. | ||||
Ref 533995 | NMDA receptor antagonists, MK-801 and ACEA-1011, prevent the development of tonic pain following subcutaneous formalin. Brain Res. 1993 Jul 2;615(2):331-4. | ||||
Ref 534392 | Preclinical characterization of MDL 27,192 as a potential broad spectrum anticonvulsant agent with neuroprotective properties. Epilepsy Res. 1997 Apr;27(1):41-54. | ||||
Ref 534607 | Treatment with the competitive NMDA antagonist GPI 3000 does not improve outcome after cardiac arrest in dogs. Stroke. 1998 Apr;29(4):824-9. | ||||
Ref 534653 | Tolerance develops to the antinociceptive and motor impairing effects of ACEA-1416, a NMDA receptor antagonist, in the formalin and rotarod test in mice. Pharmacol Res. 1998 Apr;37(4):295-302. | ||||
Ref 535378 | Amphetamine inhibits the N-methyl-D-aspartate receptor-mediated responses by directly interacting with the receptor/channel complex. J Pharmacol Exp Ther. 2002 Mar;300(3):1008-16. | ||||
Ref 535404 | Current status of neuroprotective agents in the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep. 2001 Jan;1(1):13-8. | ||||
Ref 535658 | Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep. 2003 Jan;3(1):9-20. | ||||
Ref 536058 | Emerging analgesics in cancer pain management. Expert Opin Emerg Drugs. 2005 Feb;10(1):151-71. | ||||
Ref 536300 | Anaesthetic drugs: linking molecular actions to clinical effects. Curr Pharm Des. 2006;12(28):3665-79. | ||||
Ref 536463 | The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. Epub 2007 Jul 31. | ||||
Ref 536484 | Magnesium sulfate diminishes the effects of amide local anesthetics in rat sciatic-nerve block. Reg Anesth Pain Med. 2007 Jul-Aug;32(4):288-95. | ||||
Ref 536617 | Interactions of MRZ 2/576 with felbamate, lamotrigine, oxcarbazepine and topiramate in the mouse maximal electroshock-induced seizure model. Pharmacology. 2008;81(3):259-65. Epub 2008 Feb 4. | ||||
Ref 536643 | Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor. J Med Chem. 2008 Mar 27;51(6):1534-45. Epub 2008 Feb 27. | ||||
Ref 536773 | How many modes of action should an antibiotic have? Curr Opin Pharmacol. 2008 Oct;8(5):564-73. Epub 2008 Jul 30. | ||||
Ref 536854 | Has nature already identified all useful antibacterial targets? Curr Opin Microbiol. 2008 Oct;11(5):387-92. Epub 2008 Oct 6. | ||||
Ref 536888 | Altered expression of genes involved in GABAergic transmission and neuromodulation of granule cell activity in the cerebellum of schizophrenia patients. Am J Psychiatry. 2008 Dec;165(12):1594-603. Epub 2008 Oct 15. | ||||
Ref 536934 | Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43. Epub 2008 Nov 12. | ||||
Ref 537076 | Involvement of voltage-gated sodium channels blockade in the analgesic effects of orphenadrine. Pain. 2009 Apr;142(3):225-35. Epub 2009 Feb 12. | ||||
Ref 537115 | Emerging treatments for traumatic brain injury. Expert Opin Emerg Drugs. 2009 Mar;14(1):67-84. | ||||
Ref 537702 | Quantitative studies on some antagonists of N-methyl D-aspartate in slices of rat cerebral cortex. Br J Pharmacol. 1985 Feb;84(2):381-91. | ||||
Ref 538036 | Dopamine/glutamate interactions in Parkinson's disease. Neurosci Biobehav Rev. 1997 Jul;21(4):393-400. | ||||
Ref 544121 | Molecular basis of pharmacotherapies for cognition in Down syndrome. Trends Pharmacol Sci. 2010 February; 31(2): 66. | ||||
Ref 545476 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003415) | ||||
Ref 550138 | WO patent application no. 2009,0164,86, Use of nmda receptor antagonists for treatment of urologic tumors. | ||||
Ref 551769 | Clinical pipeline report, company report or official report of VistaGen Therapeutics, Inc. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.